Therapy-induced leukemias and myelodysplastic syndromes after breast cancer treatment: an underemphasized clinical problem.
Weldon
Christopher B
CB
Department of Pharmacology, The Tulane Cancer Center, New Orleans, Louisiana, USA.
Jaffe
Bernard M
BM
Kahn
Marc J
MJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D017809:Fatal Outcome; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced*; D007953:Leukemia, Radiation-Induced / Q000209:etiology; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000139:chemically induced; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects
D013629:Tamoxifen; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate